Ming Chang1, Junguo Wang2, Hairul A Hashim1, Shihao Xie1, Adam A Malik3. 1. Exercise and Sports Science Programme, School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia. 2. Department of Orthopaedics, Qingdao Hospital of Traditional Chinese Medicine (Hiser hospital), Qingdao, Shandong, China. 3. Exercise and Sports Science Programme, School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 16150, Malaysia. adamalik@usm.my.
Abstract
OBJECTIVE: This study focused on evaluating whether high-intensity interval training (HIIT) had an effect on aerobic capacity and fatigue among patients with prostate cancer (PCa) and exploring its effect on the immune system of PCa patients. METHODS: To investigate the potential effect of HIIT on patients with prostate cancer, a meta-analysis was carried out. From January 2012 to August 2022, studies that met predefined criteria were searched in the Scopus, PubMed, Web of Science, and EBSCO databases. Analysis of the standardized mean differences was performed using Review Manager 5.4.1 software with a 95% confidence interval. RESULTS: This review examined a total of 6 articles. There were 215 male patients with PCa involved, and the mean age was 64.4 years. According to the results of the meta-analysis, the HIIT group (n = 63) had greater VO2peak (P<0.01) than the control group (CON) (n = 52) (P = 0.30, I2 = 19% in the heterogeneity test; MD, 1.39 [0.50, 2.27]). Moreover, fatigue was significantly different (P<0.01) between the HIIT (n = 62) and CON (n = 61) groups (P = 0.78, I2 = 0% in the heterogeneity test; SMD, -0.52 [-0.88, -0.16]). Furthermore, among PCa patients, HIIT showed higher efficacy (P < 0.01) in decreasing PSA than the CON regimen (P=0.22, I2 = 34% in the heterogeneity test; MD, -1.13 [-1.91, -0.34]). CONCLUSIONS: HIIT improves aerobic capacity, fatigue, and PSA levels among PCa patients but does not significantly affect IL-6 or TNF-α content. Therefore, HIIT may be a novel and potent intervention scheme for PCa patients.
OBJECTIVE: This study focused on evaluating whether high-intensity interval training (HIIT) had an effect on aerobic capacity and fatigue among patients with prostate cancer (PCa) and exploring its effect on the immune system of PCa patients. METHODS: To investigate the potential effect of HIIT on patients with prostate cancer, a meta-analysis was carried out. From January 2012 to August 2022, studies that met predefined criteria were searched in the Scopus, PubMed, Web of Science, and EBSCO databases. Analysis of the standardized mean differences was performed using Review Manager 5.4.1 software with a 95% confidence interval. RESULTS: This review examined a total of 6 articles. There were 215 male patients with PCa involved, and the mean age was 64.4 years. According to the results of the meta-analysis, the HIIT group (n = 63) had greater VO2peak (P<0.01) than the control group (CON) (n = 52) (P = 0.30, I2 = 19% in the heterogeneity test; MD, 1.39 [0.50, 2.27]). Moreover, fatigue was significantly different (P<0.01) between the HIIT (n = 62) and CON (n = 61) groups (P = 0.78, I2 = 0% in the heterogeneity test; SMD, -0.52 [-0.88, -0.16]). Furthermore, among PCa patients, HIIT showed higher efficacy (P < 0.01) in decreasing PSA than the CON regimen (P=0.22, I2 = 34% in the heterogeneity test; MD, -1.13 [-1.91, -0.34]). CONCLUSIONS: HIIT improves aerobic capacity, fatigue, and PSA levels among PCa patients but does not significantly affect IL-6 or TNF-α content. Therefore, HIIT may be a novel and potent intervention scheme for PCa patients.
Authors: James L Devin; Andrew T Sax; Gareth I Hughes; David G Jenkins; Joanne F Aitken; Suzanne K Chambers; Jeffrey C Dunn; Kate A Bolam; Tina L Skinner Journal: J Cancer Surviv Date: 2015-10-19 Impact factor: 4.442
Authors: Susan G Lakoski; Benjamin L Willis; Carolyn E Barlow; David Leonard; Ang Gao; Nina B Radford; Stephen W Farrell; Pamela S Douglas; Jarett D Berry; Laura F DeFina; Lee W Jones Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Efthymios Papadopoulos; Jenna Gillen; Daniel Moore; Darren Au; Nigel Kurgan; Panagiota Klentrou; Antonio Finelli; Shabbir M H Alibhai; Daniel Santa Mina Journal: Appl Physiol Nutr Metab Date: 2021-08-11 Impact factor: 2.665
Authors: H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter Journal: J Natl Cancer Inst Date: 2006-11-01 Impact factor: 13.506
Authors: Karen M Mustian; Catherine M Alfano; Charles Heckler; Amber S Kleckner; Ian R Kleckner; Corinne R Leach; David Mohr; Oxana G Palesh; Luke J Peppone; Barbara F Piper; John Scarpato; Tenbroeck Smith; Lisa K Sprod; Suzanne M Miller Journal: JAMA Oncol Date: 2017-07-01 Impact factor: 31.777